Peptinnovate's re-evolution in treating inflammatory diseases:Peptinnovate Limited will build on nature's ingenuity by exploiting naturally occurring molecules, which are present in ~2 billion people worldwide efficacious in treating inflammatory disease

全世界约有20亿人感染结核病细菌；它们已经进化了1000多年，通过产生调节宿主免疫系统的蛋白质，隐藏在体内。这些伴侣蛋白已被证明与身体的自然炎症过程相互作用并减少炎症过程。Peptinnovate的创新：Peptinnovate的创新方法是解锁这些蛋白质的抗炎活性，并通过进化和自然的独创性将这些蛋白质修饰成更像药物的分子，开发治疗类风湿关节炎和慢性阻塞性肺疾病（COPD）等衰弱性疾病的新药。目的：该项目将使我们的先导分子PIN201104通过临床前活动取得进展，为类风湿关节炎的1期和2期临床试验提供分子。进一步扩大在炎症关键动物模型中的疗效？在毒理学和安全性研究中证明其安全性？证明可制造性达到所要求的质量标准？主要益处、可能的结果和影响：全球炎症疾病治疗市场巨大（700亿美元），但最近的安全恐慌归因于一些关键药物。数以百万计的患者迫切需要一种具有良好安全性的新型抗炎药。Peptinnovate的方法建立在大自然的独创性和设计之上，这意味着其安全性和有效性代表了成功的高概率。这种潜在治疗选择的范式转变将对数百万患者的生活产生深远的影响，减轻医疗保健提供者的负担，并有助于建立一家总部位于英国、可持续发展的大型生物制药公司。

Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolvedover 1000’s of years to remain hidden in the body by producing proteins that modulate thehost's immune system. These chaperonin proteins have been shown to interact with andreduce the body's natural inflammatory process.Peptinnovate’s innovation:Peptinnovate’s innovative approach is to unlock the anti-inflammatory activity of theseproteins and to develop new medicines for debilitating diseases such as rheumatoid arthritisand chronic obstructive pulmonary disease (COPD) by building on evolution and nature'singenuity to modify these proteins to more drug-like molecules.Aim:This project will enable our lead molecule PIN201104 to be progressed through thepreclinical activities to deliver a molecule towards Phase 1 and 2 clinical trials in rheumatoidarthritis.Objectives:? To further expand the demonstrated efficacy in key animal models of inflammation? To demonstrate the safety in toxicology and safety studies? To demonstrate manufacturability to the desired quality standard? To prepare a suitable stable formulation for future dosing in the clinicMain benefits, likely outcomes and impacts:The worldwide market for inflammatory disease treatment is vast (>$70 billion), howeverrecent safety scares have been attributed to a number of key drugs. A novel anti-inflammatorymedicine with a benign safety profile is desperately required by millions of patients.Peptinnovate’s approach of building on nature’s ingenuity and design means that the safetyprofile and efficacy represent a high probability of success.This paradigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build alarge, UK based, sustainable biopharmaceutical company.